Medpace Q2 revenue beats estimates on backlog conversion

Medpace Holdings

22/07/2026 21:34

    

    Overview
  
US clinical research firm's Q2 revenue rose 17% yr/yr, beating analyst expectations
Q2 net income rose to $121 mln, with net income margin up to 17.2%
Company repurchased 705,616 shares for $295 mln in Q2

    

    Outlook
  
Medpace forecasts 2026 revenue between $2.805 bln and $2.885 bln
Company expects 2026 GAAP net income of $494 mln to $514 mln
Medpace projects 2026 diluted EPS of $17.25 to $17.95

    

    Result Drivers
  
BACKLOG CONVERSION - Co said Q2 revenue growth was driven by a backlog conversion rate of 24.1%
NEW BUSINESS AWARDS - Net new business awards rose 28% yr/yr to $796 mln

    
Company press release: ID:nBw8gfDyha

    

    Key Details
  

            Metric
          

            Beat/Miss
          

            Actual
          

            Consensus Estimate
          
Q2 Revenue
Beat
$707.33 mln
$687.65 mln (11 Analysts)
Q2 Net Income
 
$121.36 mln
 

    

    Analyst Coverage
  
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 11 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Medpace Holdings Inc is $480.00, about 9.7% below its July 21 closing price of $531.67
The stock recently traded at 30 times the next 12-month earnings vs. a P/E of 27 three months ago

    

    Reuters Recommended Reads
  
July 21 - Danaher Q2 revenue, adjusted EPS beats on life sciences segment strength; raises outlook
July 22 - Lonza lifts margin target, repeats latter half of 2026 to be slower
July 22 - Repligen beefs up cell therapy business with $1.5 billion deal for BioLife

    
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)